MHRA approves Imfinzi (durvalumab) + chemotherapy to treat resectable non-small cell lung cancer.-AstraZeneca
Imfinzi(durvalumab) in combination with chemotherapy has been approved in the United Kingdom for the treatment of resectable non-small cell lung cancer (rNSCLC).
The approval from the MHRA is based on positive data from the AEGEAN Phase III trial, which showed that Imfinzi (durvalumab)-based treatment before and after surgery reduced the risk of recurrence, progression events or death by 32% versus neoadjuvant chemotherapy alone.
The decision means that durvalumab is now licenced in the United Kingdom in both the resectable and unresectable non-small cell lung cancer settings which further reinforces AstraZeneca’s bold ambition to lead a revolution in oncology to redefine cancer care in the UK.
Lung cancer often goes undetected until it is in advanced stages and is the most common cause of cancer death in the UK, accounting for 21% of all cancer deaths. The UK has one of the worst five-year survival rates for lung cancer in Europe.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins